Singapore-headquartered biotechnology company Aslan Pharmaceuticals has raised $42 million in its initial public offering (IPO) in the US, according to a Nasdaq report.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
